Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)
NCT ID: NCT01337531
Last Updated: 2011-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
200 participants
INTERVENTIONAL
2011-05-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF
NCT00378001
hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF
NCT01365936
Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.
NCT00335725
A Novel Stimulation Protocol and the Conventional Low Dose Step-up and Step Down Regimens
NCT01112111
Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles
NCT05112692
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
gonadotropin
recombinant or highly purified gonadotropin
Gonal-F, Fostimon
dosage form
Gonadotropins
recombinant versus highly purified gonadotropin
Gonal-F, Fostimon
injection, daily, 10-15 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gonal-F, Fostimon
dosage form
Gonal-F, Fostimon
injection, daily, 10-15 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary infertility
* No other fertility manifestation
Exclusion Criteria
* Secondary infertility
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genesis Center for Fertility & Human Pre-Implantation Genetics
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsible party is an organization
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Savvas N Koundouros, PhD
Role: PRINCIPAL_INVESTIGATOR
Genesis Center for Fertility and Human Pre-implantation Genetics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Genesis Centre for Fertility and Human Pre-implantation Genetics
Limassol, , Cyprus
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rFSH.- HP-FSH.PCOS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.